LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotechnology firm focused on inflammatory and fibrotic diseases, has published promising preclinical data for its leading drug candidate, GRI-0621, which targets Idiopathic Pulmonary Fibrosis (IPF). The study, appearing in the American Journal of Respiratory and Critical Care Medicine, indicates GRI-0621's potential in reducing inflammation and fibrosis in the lungs.
The research utilized a mouse model to simulate pulmonary fibrosis, where GRI-0621 treatment resulted in histological improvements and a decrease in fibrosis score and lung inflammation. Notably, the treated mice exhibited lower numbers of neutrophils and lymphocytes, along with a significant reduction in the pro-fibrotic factor TGF-β and VCAM-1 levels compared to untreated controls.
IPF is a rare, chronic lung disease characterized by progressive scarring, leading to severe respiratory issues and a median survival of 3.5 years post-diagnosis. Existing treatments have limited efficacy and are associated with considerable side effects.
GRI Bio is advancing GRI-0621, a small molecule RAR-β/γ dual agonist, through a Phase 2a clinical trial. Interim data from this biomarker study is anticipated in Q3 2024, with topline results expected in Q4 2024. The company aims to address the significant unmet need in IPF treatment options.
The company's broader pipeline includes therapies targeting Natural Killer T (NKT) cells, which play a crucial role in the body's immune response. By modulating these cells, GRI Bio seeks to interrupt disease progression and restore immune system balance.
In other recent news, GRI Bio, Inc. has announced significant developments. The biotechnology firm priced its public offering, expecting gross proceeds of about $4 million. The offering includes over 2 million shares of common stock and Series C warrants, potentially bringing in an additional $8 million if fully exercised. This move is to fund product candidate development, working capital, and general corporate purposes.
Moreover, GRI Bio has initiated a 1-for-13 reverse stock split to help maintain compliance with Nasdaq's minimum bid price requirement. This strategy will reduce the total outstanding shares from approximately 6.6 million to around 508,091 shares.
The company also reported positive preclinical data for its type 2 Natural Killer T (NKT) cell activators, GRI-0803 and GRI-0124, in treating systemic lupus erythematosus. An Investigational New Drug application for GRI-0803 is planned for the second half of 2024.
In addition, GRI Bio announced positive preclinical findings for its lead compound GRI-0621, which may reduce fibrosis and inflammation in Idiopathic Pulmonary Fibrosis. A Phase 2a biomarker study of GRI-0621 is currently underway.
Finally, the company has been granted patents by the Korean Intellectual Property Office and the Canadian Intellectual Property Office, bolstering its global intellectual property portfolio.
InvestingPro Insights
In the face of GRI Bio's recent preclinical successes, the company's financial health and stock performance provide additional context for potential investors. As of the first quarter of 2024, GRI Bio holds a market capitalization of just $0.55 million, reflecting a niche position within the biotechnology sector. The company's financials indicate significant challenges, with an operating income of -$12.04 million in the last twelve months, suggesting that despite promising drug developments, the path to profitability may be strenuous.
InvestingPro Tips for GRI Bio highlight a mixed financial outlook. On the positive side, GRI Bio holds more cash than debt, which may provide some financial flexibility as it advances clinical trials. However, the company is quickly burning through cash, which could present a risk to continued operations without additional funding or partnerships. Moreover, the stock has experienced substantial declines, with a staggering 99.51% drop in its one-year price total return as of the same period, signaling investor concerns over the company's future prospects.
For those considering an investment in GRI Bio, it is essential to weigh the potential of GRI-0621 against the company's financial health and market performance. With the stock currently in oversold territory according to the Relative Strength Index (RSI), there may be opportunities for investors willing to absorb a higher level of risk. To explore further InvestingPro Tips related to GRI Bio, which could provide deeper insights into the company's financials and stock performance, visit https://www.investing.com/pro/GRI. Remember to use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. There are 15 additional InvestingPro Tips listed in InvestingPro that could guide investment decisions regarding GRI Bio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.